Pasireotide versus octreotide in acromegaly: a head-to-head superiority study

What Was Tested

This randomized controlled trial paper looks at Octreotide and Somatostatin.

With current medical therapies, including the gold standard octreotide long-acting-release (LAR), many patients do not achieve biochemical control.

Who Took Part

The study group was 358 patients.

PubMed indexes the participants as teenagers, young adults, adults, middle-aged adults, older adults and people over 80, both men and women.

How the Study Was Run

In design terms this was a randomized and double-blind study.

Because people in this Octreotide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Octreotide study, the assignments were hidden from both participants and investigators until the end.

The researchers conducted a prospective, randomized, double-blind study at 84 sites in 27 countries.

What Was Measured

The subject headings attached to it are Acromegaly, Adenoma, Antineoplastic Agents, Hormonal, Growth Hormone-Secreting Pituitary Adenoma, Octreotide, Somatostatin and Therapeutic Equivalency.

What This Means in Plain Language

The paper is a randomized and double-blind study of Octreotide and Somatostatin in 358 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2014 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Octreotide compound page and the Somatostatin compound page, all human trials.